HC Wainwright set a $3.00 price objective on Lipocine (NASDAQ:LPCN) in a research report report published on Monday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, Canaccord Genuity reaffirmed a hold rating and set a $1.50 price target on shares of Lipocine in a report on Friday, August 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Lipocine has a consensus rating of Buy and an average price target of $6.38.

Shares of LPCN opened at $1.39 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 7.40 and a current ratio of 7.40. The company has a market cap of $30.91 million, a PE ratio of -1.32 and a beta of 0.41. Lipocine has a 12-month low of $1.03 and a 12-month high of $3.74.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.12. Analysts anticipate that Lipocine will post -0.68 earnings per share for the current year.

A hedge fund recently raised its stake in Lipocine stock. JPMorgan Chase & Co. increased its stake in shares of Lipocine Inc (NASDAQ:LPCN) by 145.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 95,429 shares of the specialty pharmaceutical company’s stock after purchasing an additional 56,606 shares during the quarter. JPMorgan Chase & Co. owned 0.44% of Lipocine worth $132,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 13.33% of the company’s stock.

About Lipocine

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Featured Story: What is a stock split?

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.